Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Accumulated Depreciation (2022 - 2025)

Mereo BioPharma (MREO) has disclosed Accumulated Depreciation for 4 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation rose 14.33% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, up 14.33% year-over-year, with the annual reading at $1.1 million for FY2025, 14.33% up from the prior year.
  • Accumulated Depreciation for Q4 2025 was $1.1 million at Mereo BioPharma, up from $1.0 million in the prior quarter.
  • The five-year high for Accumulated Depreciation was $1.1 million in Q2 2025, with the low at $736000.0 in Q4 2022.
  • Average Accumulated Depreciation over 4 years is $942000.0, with a median of $956500.0 recorded in 2024.
  • Peak annual rise in Accumulated Depreciation hit 26.57% in 2025, while the deepest fall reached 8.61% in 2025.
  • Over 4 years, Accumulated Depreciation stood at $736000.0 in 2022, then increased by 8.7% to $800000.0 in 2023, then increased by 18.62% to $949000.0 in 2024, then rose by 14.33% to $1.1 million in 2025.
  • According to Business Quant data, Accumulated Depreciation over the past three periods came in at $1.1 million, $1.0 million, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.